
News|Videos|December 8, 2020
Further Testing Rivipansel and Its Implications Through the RESET Clinical Trial
Helen Thackray, MD, dives deeper into how the researchers tested rivipansel on the study participants and the implications compared to previous trials.
Advertisement
Pharmacy Times interviewed Helen Thackray, MD, on her presentation at the 62nd ASH Annual Meeting and Exposition. The presentation discusses research into rivipansel for acute vaso-occlusive crisis in sickle cell disease and the RESET clinical trial. In this video, Thackray dives deeper into how the researchers tested rivipansel on the study participants and the implications compared to previous trials.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
US Measles Cases Climb, Raising Questions About Preparedness and Prevention
2
FDA Awards National Priority Voucher to Teclistamab Plus Daratumumab in Relapsed/Refractory Multiple Myeloma
3
Afamitresgene autoleucel: The First T-Cell Receptor Therapy on the Market
4
Soaring off the Patent Cliff: Preparing for the Next Wave of Oncology Biosimilars
5










































































































































































































